Drug costs for some U.S. seniors to rise by hundreds of dollars

Medicare Part D's catastrophic coverage threshold will go up by $1,250 next year.
OCT 11, 2019
By  Bloomberg
Senior citizens with high prescription drug costs are facing hundreds of dollars in additional expenses next year, according to a new analysis of Medicare's drug program by a nonprofit research group. Medicare's drug benefit, known as Part D, is complicated. Patients in the program have a deductible where they must pay 100% of the cost: $435 in 2020, according to the analysis by the Kaiser Family Foundation. After that, they pay a quarter of the costs until they reach the threshold for catastrophic coverage, when richer benefits kick in. Next year, the catastrophic coverage threshold will go up by $1,250 — meaning people on brand-name drugs will pay about $400 more a year out-of-pocket, according to the analysis. People taking generics will pay even more. High drug costs are a source of discontent among voters. Vying for 2020 voters, the Trump administration has boasted about its efforts to get pharmaceutical companies to lower list prices for medications, while ire at drugmakers and insurers has animated Democratic calls for a broader health care overhaul. Next year's rising costs stem from an expiring part of the Affordable Care Act, which temporarily tamped down increases in the catastrophic coverage threshold. Medicare Part D covers about 44 million Americans on the federal health program for the elderly and disabled. Administered by private insurers, the program distributes the cost of medications among enrollees, health plans, drugmakers and the government. Low-income people in the program get subsidies to help with costs. In 2017, 4.9 million people had drug spending and incomes high enough that they either entered the coverage gap or went all the way through it, according to the Kaiser Family Foundation. [Recommended video: How to help clients make it through retirement] Above the catastrophic coverage level, seniors are on the hook for 5% of medication costs, with no upper limit. Various legislative proposals would cap total out-of-pocket costs for the Medicare drug benefit. A bill supported by Democratic House Speaker Nancy Pelosi would limit seniors' exposure to $2,000, while a proposal advanced by the Republican-controlled Senate Finance Committee would set the limit at $3,200. The Trump administration has also proposed insulating seniors from cost-sharing after they reach the catastrophic threshold. Whether Congress and the administration can agree on a prescription drug bill before the 2020 election remains an open question. If they don't, some seniors may realize they're paying more for their medicine, just as their preparing to go to the polls.

Latest News

New York Dems push for return of tax on stock sales
New York Dems push for return of tax on stock sales

The looming threat of federal funding cuts to state and local governments has lawmakers weighing a levy that was phased out in 1981.

Human Interest and Income Lab streamline workflows for retirement-focused advisors
Human Interest and Income Lab streamline workflows for retirement-focused advisors

The fintech firms' new tools and integrations address pain points in overseeing investment lineups, account monitoring, and more.

Buy or sell Canada? Wealth managers watch carefully as Canadians head to the polls
Buy or sell Canada? Wealth managers watch carefully as Canadians head to the polls

Canadian stocks are on a roll in 2025 as the country prepares to name a new Prime Minister.

Carson, Lido strengthen RIA networks with bicoastal deals
Carson, Lido strengthen RIA networks with bicoastal deals

Carson is expanding one of its relationships in Florida while Lido Advisors adds an $870 million practice in Silicon Valley.

Goldman gets shareholder backing on $80M executive bonus packages
Goldman gets shareholder backing on $80M executive bonus packages

The approval of the pay proposal, which handsomely compensates its CEO and president, bolsters claims that big payouts are a must in the war to retain leadership.

SPONSORED Compliance in real time: Technology's expanding role in RIA oversight

RIAs face rising regulatory pressure in 2025. Forward-looking firms are responding with embedded technology, not more paperwork.

SPONSORED Advisory firms confront crossroads amid historic wealth transfer

As inheritances are set to reshape client portfolios and next-gen heirs demand digital-first experiences, firms are retooling their wealth tech stacks and succession models in real time.